牧原股份(002714.SZ):目前已投產10家屠宰廠,投產產能合計2,900萬頭/年
格隆匯5月17日丨牧原股份(002714.SZ)近日在公司2023年度網上業績説明會上表示,公司目前已投產10家屠宰廠,投產產能合計2,900萬頭/年。公司屠宰肉食業務已經歷前期產能高速發展階段,後續新增產能將會視外部市場情況及內部經營情況綜合決策。公司將繼續提升已投產屠宰廠的運營效率,提高產能利用率,從市場開拓、渠道建設、人才培養、內部運營管理等方面發力,增強屠宰肉食業務的盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.